Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith M Skubitz

Showing results (1-10 of 64) with videos related to

Pageof 7
Sort By:
Cancer Investigation|May 15, 2003
Phase II trial of pegylated-liposomal doxorubicin (Doxil) in sarcomaKeith M Skubitz
The Oncologist|April 12, 2019
Cardiotoxicity Monitoring in Patients Treated with Tyrosine Kinase InhibitorsKeith M Skubitz
Mayo Clinic Proceedings|June 6, 2017
Biology and Treatment of Aggressive Fibromatosis or Desmoid TumorKeith M Skubitz
Cancer Investigation|August 29, 2002
Phase II trial of pegylated-liposomal doxorubicin (Doxil) in mesotheliomaKeith M Skubitz
Investigational New Drugs|May 11, 2002
Phase II trial of pegylated-liposomal doxorubicin (Doxil) in renal cell cancerKeith M Skubitz
Current Treatment Options in Oncology|May 3, 2014
Giant cell tumor of bone: current treatment optionsKeith M Skubitz
European Journal of Clinical Investigation|December 15, 2024
The role of CEACAMs in neutrophil functionKeith M Skubitz
Cureus|April 4, 2024
RAD51C and MYST3 Mutations in a Case of Desmoid-Type Fibromatosis With No Mutation in CTNNB1 or APCKeith M Skubitz, Paari Murugan
Journal of Pediatric Hematology/Oncology|July 26, 2018
Long-term Outcome After Doxorubicin and Ifosfamide Overdose in a Patient With Osteosarcoma and BARD1 MutationMalvi Savani, Keith M Skubitz
Biology|December 30, 2025
Evolution of CEACAM1 N Domain Biologically Active Sites in PrimatesKeith M Skubitz, Wolfgang Zimmermann
Pageof 7

Showing results (1-10 of 64) with videos related to

Sort By:
Pageof 7
Cancer Investigation|May 15, 2003
Phase II trial of pegylated-liposomal doxorubicin (Doxil) in sarcomaKeith M Skubitz
The Oncologist|April 12, 2019
Cardiotoxicity Monitoring in Patients Treated with Tyrosine Kinase InhibitorsKeith M Skubitz
Mayo Clinic Proceedings|June 6, 2017
Biology and Treatment of Aggressive Fibromatosis or Desmoid TumorKeith M Skubitz
Cancer Investigation|August 29, 2002
Phase II trial of pegylated-liposomal doxorubicin (Doxil) in mesotheliomaKeith M Skubitz
Investigational New Drugs|May 11, 2002
Phase II trial of pegylated-liposomal doxorubicin (Doxil) in renal cell cancerKeith M Skubitz
Current Treatment Options in Oncology|May 3, 2014
Giant cell tumor of bone: current treatment optionsKeith M Skubitz
European Journal of Clinical Investigation|December 15, 2024
The role of CEACAMs in neutrophil functionKeith M Skubitz
Cureus|April 4, 2024
RAD51C and MYST3 Mutations in a Case of Desmoid-Type Fibromatosis With No Mutation in CTNNB1 or APCKeith M Skubitz, Paari Murugan
Journal of Pediatric Hematology/Oncology|July 26, 2018
Long-term Outcome After Doxorubicin and Ifosfamide Overdose in a Patient With Osteosarcoma and BARD1 MutationMalvi Savani, Keith M Skubitz
Biology|December 30, 2025
Evolution of CEACAM1 N Domain Biologically Active Sites in PrimatesKeith M Skubitz, Wolfgang Zimmermann
Pageof 7